Administration of VEGF-VEGFR inhibitor VEGFR1-Fc in combination with CD47 blocking fusion protein generated synergistic antitumor efficacy, highlighting the potential therapeutic strategies for NSCLC via blocking angiogenetic axis and CD47/SIRPα anti-phagocytic axis. The gene discussed is KDR; the disease is non-small cell lung carcinoma.